Biomarker Panel Predicts Hepatocellular Carcinoma Treatment Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hepatocellular carcinoma (HCC) lack effective biomarkers to predict patient responsiveness to treatments, particularly for advanced disease, necessitating a method to identify patients likely to respond to chemotherapy.

Innovation Solution

Determining the levels of biomarkers such as TCF-4, WISP2, ASPH, IRS1, MAPK12, CLDN2, JAG1, GPR56, ANXA1, CAMK2N1, STK17B, SPP1, AXIN2, MMP7, CADM1, PLCD4, and CD24 in biological samples to predict responsiveness to treatment compounds like thalidomide and lenalidomide.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current treatments for hepatocellular carcinoma are used, then patients receive standard therapy, but there is no effective biomarker to predict patient responsiveness to treatment

Engineering Contradiction:

Improveprediction accuracy of treatment responsivenessVSAvoidlack of biomarker information for treatment selection

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent performs preliminary determination of biomarker levels (TCF-4, WISP2, ASPH, IRS1, MAPK12, CLDN2, JAG1, GPR56, ANXA1, CAMK2N1, STK17B, SPP1, AXIN2, MMP7, CADM1, PLCD4, CD24) in patient samples before treatment initiation. This preliminary action enables prediction of treatment responsiveness in advance, allowing clinicians to select appropriate therapies before administering them, thereby resolving the lack of predictive biomarker information.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent introduces biomarkers as intermediary molecules that mediate between the patient's tumor characteristics and the treatment response outcome. These biomarkers serve as measurable intermediaries that provide information about how a patient's tumor will respond to specific treatments, bridging the gap between current treatment options and individual patient outcomes.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If biomarker determination methods are developed, then patient responsiveness can be predicted, but the complexity of measuring multiple biomarkers increases

Engineering Contradiction:

Improveaccuracy of treatment response predictionVSAvoidcomplexity of biomarker measurement system

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the complex task of predicting treatment responsiveness into multiple independent biomarker measurements. Instead of attempting to measure a single complex parameter, the method divides the prediction into 17 distinct biomarker assessments (TCF-4, WISP2, ASPH, IRS1, MAPK12, CLDN2, JAG1, GPR56, ANXA1, CAMK2N1, STK17B, SPP1, AXIN2, MMP7, CADM1, PLCD4, CD24), each contributing specific predictive information. This segmentation allows for systematic measurement and interpretation of treatment responsiveness.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS8901110B2Use of biomarkers in methods for the treatment of hepatocellular carcinoma

Publication Date: 2014.12.02 CELGENE CORP

AI summary

Provided herein are biomarkers for hepatocellular carcinoma and uses thereof.